45 results about "Immunomodulin" patented technology

Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.

The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.

The invention relates to application of recombined ganoderma lucidum immnoregulation protein (rLZ-8) in preparation of medicine for treating melanin tumor. In-situ tumor and metastatic tumor experiment animal models are used to research anti-tumor effect of rLZ-8, and the results show that the rLZ-8 can evidently inhibit in-situ tumor growing and metastasis forming of the melanin tumor.

The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.

The invention discloses an application of a recombined ganoderma lucidum immunomodulatory protein in preparing a drug for treating parkinsonism. In-vivo animal tests show that the recombined ganoderma lucidum immunomodulatory protein can improve the behavioral disorder of a Parkinson animal model, has a certain neuroprotective effect on brain tissue dopaminergic neuron cell of the Parkinson animal model, and can prevent and treat parkinsonism.

The invention relates to the field of biological pharmacy and in particular relates to preparation and application of ganoderma lucidum immunoregulatory protein and fusion protein by a gene engineering technological means. A series of experiments show that an in-vivo half-life period prolonging effect of the fusion protein is more remarkable than that of rLZ-8, an improvement effect of the biological activity of the fusion protein is more remarkable than that of the rLZ-8, and in particular, and a leukocyte number increasing effect and an anti-tumor effect of the fusion protein are more remarkable than those of the rLZ-8 in the aspects of treating leucopenia and resisting tumor.

The invention relates to an application of a recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure. According to the invention, a rat cardiac failure model is established by intraperitoneal injection of adriamycin amycin (ADR) to study the curative effect of rLZ-8 to chronic cardiac failure. Experimental research results show that rLZ-8 can remarkably improve the cardiac function of the rat cardiac failure model, reduce the rate of myocardial apoptosis, reduce expression of relevant apoptin in myocardial cells (caspase3 and caspase9) and increase the survival rate of rats with chronic heart failure.

Provided are immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infections agents containing nucleic acid encoding the immunomodulatory proteins. In some embodiments, the immunomodulatory proteins are secretable. In some embodiments, the immunomodulatory proteins are transmembrane proteins that are surfaceexpressed. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

The invention relates to a method for producing a trametes versicolor immunomodulatory protein by virtue of a pichia pastoris expression system. Problems about the preparation of trametes versicolor immunomodulatory proteins are effectively solved. The method comprises the following steps of synthesizing a nucleotide sequence SEQ ID NO.1 of a trametes versicolor immunomodulatory protein FIP-tvc according to a codon usage bias of pichia pastoris; constructing a recombinant expression plasmid X-FIP-tvc by virtue of the trametes versicolor immunomodulatory protein FIP-tvc synthesized by restriction enzyme digestion and an expression plasmid vector X, linearizing the recombinant expression plasmid X-FIP-tvc by virtue of a restriction enzyme, then transforming a competent cell of pichia pastoris GS115, screening a constitutive positive transformant or inducible positive transformant by virtue of an antibiotic-containing plate and PCR (Polymerase Chain Reaction) method, selecting an inducible high-level rFIP-tvc secretion expression pichia pastoris recombinant strain, performing fermental cultivation or induction expression for 3 to 7 days, precipitating fermentation supernatant with ammonium sulfate, performing dialysis on precipitates for 24 to 48 hours, performing affinity exchange chromatography with a chromatographic column, and performing drying to obtain solid powder of the trametes versicolor immunomodulatory protein FIP-tvc. The method is low in cost, short in cycle, easy to implement technically, suitable for industrial production and high in purity.

The invention relates to an application of recombinant ganoderma lucidum immunomodulatory protein rLZ-8 in treating lung cancer, laryngocarcinoma and brain glioma. According to the invention, the in-vivo anti-tumor effect of the rLZ-8 is researched by respectively building a lung cancer mice model by virtue of a caudal vein injection method and building a laryngocarcinoma and brain glioma nude mice animal model by virtue of a subcutaneous transplantation tumor method; a treatment result indicates that the rLZ-8 achieves an obvious anti-tumor effect on the lung cancer, the laryngocarcinoma and the brain glioma.

The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.

The invention provides a method of producing a non-immunogenic (bio)engineered tissue from pluripotent stem cells or pluripotent stem cell derivatives, the respective cells being deficient of MHC class I molecules and comprising an immunomodulatory protein on their surface, wherein the method comprises inducing the differentiation of the pluripotent stem cells into a cell type that is essential for the function of the engineered tissue under conditions that also allow the formation of the engineered tissue, thereby rendering the engineered tissue to be non-immunogenic to a recipient of the engineered tissue. The present invention further relates to an engineered tissue, a pharmaceutical composition comprising the engineered tissue, medical treatments using the engineered tissue and uses of the engineered tissue.

Provided are plasmid vector constructs encoding multiple immunomodulatory proteins where each protein or component thereof can be expressed utilizing appropriate promotors and / or translation modifiers. Additional immunomodulatory proteins and genetic adjuvants containing shared tumor antigens can be added to further therapeutic potential as well as allow tracking of therapeutic treatment. Also provides are methods of expressing the plasmid constructs.

The invention provides a novel application of a recombinant ganoderma lucidum immunological regulation protein (rLZ-8) in treating thrombopenia. In the experiments of preventing and treating the thrombopenia of rats and dogs caused by cyclophosphamide, the rLZ-8 prepared from physiological saline carries out administration on an experimental animal model with lower thrombocytes, THPO and IL-6 areused as positive medicines, continuous administration is carried out, the number of the thrombocytes in blood is detected, the changes of the number of the thrombocytes before and after therapy are contrasted, and the medicine effect is analyzed. Compared with a model group, the rLZ-8 medicine group already obviously stimulates the thrombocyte proliferation of rats, Guinea pigs and dogs in the initial period (the 3rd day to the 5th day) of the administration, the difference is very obvious, the thrombocytes are recovered to a normal level in the middle period (the 7th day to the 10th day) of the administration, and the invention also obtains a very good effect in treating the thrombopenia of a Guinea pig experimental animal model caused by injecting anti-thrombocyte serum.

Disclosed is a ganoderma lucidum immunomodulatory protein mutant. The ganoderma lucidum immunomodulatory protein mutant comprises FIP-gluMN31S, FIP-gluMT36N and FIP-gluMN31S / T36N, wherein the amino acid sequence and the nucleotide sequence of the FIP-gluMN31S are shown as SEQ ID NO.1 and SEQ ID NO.4 respectively; the amino acid sequence and the nucleotide sequence of the FIP-gluMT36N are as shown in SEQ ID NO.2 and SEQ ID NO.5 respectively; and the amino acid sequence and the nucleotide sequence of the FIP-gluMN31S / T36N are shown as SEQ ID NO. 3 and SEQ ID NO. 6 respectively. According to the mutant, the problem that the toxicity of FIP-glu in application to cells is relatively high can be solved, the toxicity of the modified mutant to the cells is remarkably reduced compared with that of ganoderma lucidum immunomodulatory protein (FIP-glu), and the utilization value of the mutant can be effectively improved.

The invention is applicable to the technical field of gene engineering. The invention provides an immunomodulatory protein mutant and a nucleotide sequence thereof, a recombinant plasmid vector, an engineering bacterium, a construction method and application. The amino acid sequence of the immunomodulatory protein mutant is obtained by mutating phenylalanine at the 8th site into tryptophan on thebasis of the amino acid sequence of immunomodulatory protein LZ-8 shown as SEQ ID NO.1, and the mutated amino acid sequence is shown as SEQ ID NO.2. According to the invention, the thermal stability of the recombinant LZ-8 and the stability of the recombinant LZ-8 patent medicine are further improved on the basis that the immunomodulatory activity and the anti-tumor activity are basically unchanged; on one hand, the heat stability of the immunomodulatory protein mutant is greatly improved, and compared with wild type LZ-8, the F8W phase transition temperature Tm is increased by 1.86 DEG C, andthe phase transition enthalpy value delta H is increased by 39.19 kJ / mol; and on the other hand, the immunomodulatory protein mutant has immunomodulatory activity and anti-tumor activity consistent with those of wild type LZ-8, and has higher application and development value compared with the prior art.

The present invention relates to a method for treating a refractory or relapsed lung cancer. Particularly, the invention provides a method and a formulation of using an immunomodulatory protein derived from Ganoderma microsporum in the treatment of a refractory or relapsed lung cancer.

The invention relates to Favolus arcularius Ames immunomodulatory protein Fip-Par1 and a preparation method and application thereof. The amino acid sequence of the immunomodulatory protein is defined as SEQ ID NO.1. The preparation method comprises the steps: (1) connecting the cDNA sequence of the Favolus arcularius Ames immunomodulatory protein into a carrier, and obtaining a recombinant vector; (2) converting the recombinant vector to a host cell, and obtaining a recombination strain; (3) cultivating the recombination strain, inducing and recombining the expression of the Favolus arcularius Ames immunomodulatory protein Fip-Par1; and (4), obtaining through the NI column purification and the dialysis segregation. The immunomodulatory protein is used for preparing health food. The Favolus arcularius Ames immunomodulatory protein Fip-Par1 obtained by recombination in vitro is capable of remarkably promoting the immunomodulatory effects, such as spleen lymphocyte proliferation and expression of tumor necrosis factor TNF-a, and has application potential for improving the body immunity.

The invention discloses application of recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in androgenetic alopecia. In-vivo animal model experiments show that the recombinant ganoderma lucidum immunoregulatory protein is capable of improving depilation of an androgenetic alopecia anomal model and can be used for preventing and treating androgenetic alopecia. The recombinant ganoderma lucidum immunoregulatory protein disclosed by the invention is a high-purity protein substance prepared through a recombination technology and a yeast cell eukaryotic expression system.

The invention relates to Favolus arcularius Ames immunomodulatory protein Fip-Par1 and a preparation method and application thereof. The amino acid sequence of the immunomodulatory protein is defined as SEQ ID NO.1. The preparation method comprises the steps: (1) connecting the cDNA sequence of the Favolus arcularius Ames immunomodulatory protein into a carrier, and obtaining a recombinant vector; (2) converting the recombinant vector to a host cell, and obtaining a recombination strain; (3) cultivating the recombination strain, inducing and recombining the expression of the Favolus arcularius Ames immunomodulatory protein Fip-Par1; and (4), obtaining through the NI column purification and the dialysis segregation. The immunomodulatory protein is used for preparing health food. The Favolus arcularius Ames immunomodulatory protein Fip-Par1 obtained by recombination in vitro is capable of remarkably promoting the immunomodulatory effects, such as spleen lymphocyte proliferation and expression of tumor necrosis factor TNF-a, and has application potential for improving the body immunity.

The invention belongs to the field of biotechnology and immunology, and particularly relates to a duck-derived innate immunomodulatory protein DDX3X for regulating and controlling an innate immune signal pathway in duck embryo fibroblasts (DEF), participating in antiviral reaction and playing a role in duck antiviral infection. It is proved in the DEF that overexpression of duck-derived DDX3X caninduce generation of duck I-type interferon by activating transcription factors including IRF1 and Nf-kappa B; after the background expression of DDX3X is interfered, the activity of poly(I: C) and DTMUV induced I-type interferon is also obviously reduced; and the overexpression of DDX3X can be used for remarkably inhibiting the proliferation of the DTMUV (Duck tembusu virus). The invention further discloses that the duck-derived DDX3X is expected to become a novel target for treating duck inflammatory diseases, and can be applied to the preparation of drugs with the effect of inhibiting DTMUVproliferation; the duck-derived DDX3X can also be used as an immunomodulator for duck virus diseases.

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGFβRII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.

The subjects of the invention are a cancer health caring food combination determining method and a non-instantaneous computer readable storage medium. The invention discloses the cancer health caringfood combination determining method and the non-instantaneous computer readable storage medium for utilization of persons with cancers as possible. The cancer health caring food combination determining method comprises the following steps of: a nucleic acid detecting step, detecting the nucleic acid in a biological sample, and determining a possibility of affecting the cancer according to the detecting result of the nucleic acid; a cancer detecting step, detecting a tumor index and at least one health index in a blood sample, and determining a fact that the cancer is not affected according toa detecting result of a tumor index; and a cancer health caring food combination determining step, determining the cancer health caring food combination according to the cancer affecting possibility in the nucleic acid detecting step and at least one health index in the cancer detecting step, wherein the cancer health caring food combination comprises multiple kinds of health caring food, and at least one kind of health caring food is an immunomodulatory protein or a compound of the immunomodulatory protein.

The invention discloses a recombinant Ganoderma Lucidum immunomodulatory protein (rLZ-8) which has anti-tumor effect and is expressed by Pichia pastoris, and a pharmaceutical preparation thereof. The rLZ-8 has the effect of directly killing or damaging NB4 or K562 or HL-60 or S180 or H22 cells and not affecting normal cells; and the rLZ-8 can quickly and efficiently induce a plurality of tumor cells to apoptosize in vitro, can also effectively kill the tumor cells in a body of a mouse tumor model, has no obvious toxic side effect, and can keep or raise the level of leucocytes. In addition, the invention also provides an anti-tumor pharmaceutical preparation type taking the rLZ-8 as a core composition.

Provided are expression vector constructs encoding multiple immunomodulatory proteins where each protein or component thereof can be expressed utilizing appropriate promoters and / or translation modifiers. Additional immunomodulatory proteins and genetic adjuvants containing shared tumor antigens can be added to further therapeutic potential as well as allow tracking of therapeutic treatment. Alsoprovided are methods of use for the expression vectors.

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in reducing damage caused by fine particulate matter on embryos and offspring. Accordingly, the present invention suggests that the Ganoderma immunomodulatory protein administrated to pregnant animals can prevent neurological damages and reduce risk of disorders in embryos and offspring.